Agenda
A focus on bladder, kidney and prostate cancers.
The World GU agenda is presented by multidisciplinary thought leaders who will present the latest insights, debate hot topics, and participate in panel discussions and audience Q&As. Attendees receive up to 11.75 CE credits.
Thursday | August 21
Poster Session & Welcome Reception
- 6:00 PM - 9:00 PM
- Curb Conservatory & Hall of Fame Rotunda
Friday | August 22
World GU Agenda
Breakfast Symposium (Non-CE)
- Event Hall
- SESSION 1
- CMA Theater
MDT Advancements in Staging and Treatment Planning in GU Cancers
- 8:45 AM - 9:05 AM
Theranostics in Prostate: Critical Role of Imaging
Panel Discussion
- 9:05 AM - 9:25 AM
How Do You Define Locally Advanced Bladder Cancer?
Panel Discussion
Diagnosis and Management of Indeterminant Metastasis in Kidney Cancer
Panel Discussion and Q&A
Networking Break
- Grand Foyer
- SESSION 2
- CMA Theater
Managing Early-Stage Disease
Early-Stage Kidney: Surgery, Ablation and Active Surveillance
Early-Stage Bladder: The Evolving Landscape
Early-Stage Prostate: Novel Diagnostics, Focal Therapy and Active Surveillance
Radiation Chip Shots: Small Tumors and Localized Disease
Panel Discussion and Q&A
Lunch Symposium (Non-CE)
- Event Hall
- SESSION 3
- CMA Theater
Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part I: Maximizing MDT Resources
Case-Based Approach to Oligometastatic Renal Disease
Case-Based Approach to Locally Advanced Bladder Cancer
The Current State of mHSPC: Volume of Disease and Treatment Management
Risk Stratification and Future Developments in Precison Management of Prostate Cancer
Panel Discussion and Q&A
Networking Break
- Grand Foyer
- SESSION 4
- CMA Theater
Multidisciplinary Care of High-Risk Patients in GU Cancers
Point/Counterpoint: High-Risk Kidney Cancer
Panel Discussion
Point/Counterpoint: High-Risk Prostate Cancer
Panel Discussion
Point/Counterpoint: High-Risk Bladder Cancer
Panel Discussion and Q&A
- SESSION 5
- CMA Theater
Classifying and Managing Rare Histologies Across GU Cancers
Classifying Rare Histologies
How do you Manage Rare Bladder Histologies?
Managing Upper Tract Urothelial Carcinoma
Management of Rare Kidney Histologies
Panel Discussion and Q&A
- SESSION 6
- CMA Theater
Keynote Presentation (Non-CE)
Chaunté Lowe
4x Olympian
Founder & CEO
Boundless Resilience
Saturday | August 23
Breakfast Symposium (Non-CE)
- Event Hall
- SESSION 7
- CMA Theater
Tool's for Tomorrow's Oncologist
Role of Precision Medicine
Trials in Progress in Early-Stage Therapeutics
Patient Frailty/FIT Levels
Palliative Care & Decision Making
Healthcare Policy
Implementing Pathways in an Evolving Landscape
Q&A
Networking Break
- Grand Foyer
- SESSION 8
- CMA Theater
Strategies for the Implementation of MRD in GU Cancers
Defining MRD
Strategies for Implementing MRD
What's Different in Prostate?
How Can We Better Measure MRD in Kidney?
Panel Discussion and Q&A
Lunch Symposium (Non-CE)
- Event Hall
- SESSION 9
- CMA Theater
Case-Based Real-World Management and Therapeutic Interventions in GU Cancers- Part 2
Case-Based Approach to PARP ihibitors in Prostate Cancer
Case-Based Approach to Kidney Cancer
Bladder MIBC Systemic Therapy and Outcomes
Panel Discussion and Q&A
- SESSION 10
- CMA Theater
Early-Stage Therapeutics: New Drugs in the Contemporary Landscape
Emerging Approaches to Bladder Cancer
Emerging Approaches to Prostate Cancer
Emerging Approaches to Kidney Cancer
NCI Intramural Prostate Cancer Studies
Q&A
Networking Break
- Grand Foyer
- SESSION 11
- CMA Theater
Applying the Good News into Everyday Practice
MDT Panel on Monday Morning Quick Start
- SESSION 12
- CMA Theater
Final Jeopardy!
Farewell Reception
- Event Hall
Let's join the biggest marketing conference on 2022.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
